Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genomic Response to Glucocorticoids in Healthy Volunteers
NCT02798523Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jan 2017
- Primary completion
- May 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of methylprednisolone in autoimmune diseases (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Number of Participants Sampled for RNA-seq Differential Expression Analysis (Biological Replicates). Started Jan 2017; status: completed.
02
Drugs
methylprednisolone
03
Conditions
autoimmune diseases
Beyond the preview
Go deeper on NCT02798523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02798523.